A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients.

A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients. - A RCT of anticoagulant agents for prevention of VTE after THA in elderly or underweight or moderate renal insufficient patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026819

Enrollment

Registered

2017-04-01

Start date

2016-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis of the hip, osteonecrosis of the femoral head, femoral neck fracture, rheumatoid arthritis, rapidly destructive coxarthropathy, septic arthritis of the hip

Interventions

Dose: Edoxaban group

Edoxaban 15mg per day Enoxaparin gropu

Enoxaparin 2000 IU per day Intervention period: for 10 days after the surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. elderly; over 75 years old and/or 2. low weight; 40 kg < BW < 50 kg and/or 3. Moderate renal function disorder; 30 mL/min < Ccr < 50 mL/min

Exclusion criteria

Exclusion criteria: 1. Ccr < 30 mL/min 2. common use of anticoagulant, antiplatelet and the P glucoprotein repressor 3. perioperative amount of bleeding more than 600 ml 4. allergic to iodine contrast agent 5. Under 20 years old 6. inappropriate as a study subject

Design outcomes

Primary

Measure	Time frame
VTE incidence on the 6th to 8th postoperative day.	—

Countries

Japan

Contacts

Public ContactTomoaki Sanki

Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Department of Orthopaedic Surgery

sanki753@gmail.com086-235-7273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026